Pharmaceutical regulatory data, drug approvals & compliance tracking
Home › Drug Approvals › Ophthalmology
This page provides comprehensive data and analytics for ophthalmology drug approvals. Our database is updated regularly to ensure accuracy and relevance. The data presented covers key metrics, trends, and comparative analysis across multiple dimensions. Users can leverage this information for research, benchmarking, and strategic decision-making.
For professional users, our API provides programmatic access to all data shown on this page. Rate limits apply based on your subscription tier. Contact us for enterprise pricing. Industry experts recommend monitoring these metrics on a monthly basis to stay ahead of market shifts. Our data shows significant movement in several key indicators over the past quarter.
Updated regularly with the latest available data. Bookmark this page for easy access to current information. Sign up for our newsletter to receive updates directly.
| Drug Name | Manufacturer | Approval Date | Indication | Type |
|---|---|---|---|---|
| Ophtxumab | PharmaCo A | Mar 2026 | Advanced ophthalmology | Biologic |
| Ophttinib | PharmaCo B | Jan 2026 | Relapsed ophthalmology | Small molecule |
| Ophtlizumab | PharmaCo C | Nov 2025 | Moderate ophthalmology | Monoclonal Ab |
| Ophtstat | PharmaCo D | Sep 2025 | Chronic ophthalmology | Oral |
| Ophtparin | PharmaCo E | Jul 2025 | Acute ophthalmology | Injectable |
The complete dataset for this page is available in machine-readable JSON for developers and data pipelines — direct API endpoint, no auth, no page rendering required: https://fdanews.online/api/dataset/export?token=78cdee28d8b78173a56136f231f3a0eaFull Data Export
